Key populations brief
Accessed November 2017
Health Evidence Network synthesis report 53
Global Plan to end TB 2016-2020
Journal of the International Association of Providers of AIDS Care 2017, Vol. 16(3) 226–232
SDG target 3.3: by 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, waterborne diseases and other communicable diseases.
Overcoming HIV-related stigma and discrimination in health- care settings and beyond
UNAIDS 2017 | REFERENCE
Blueprint for EECA countries, first edition
Practical Guidance for collaborative interventions
В борьбе с туберкулезом достигнуты значительные прорывы, среди которых ускоренные и более точные методы диагностики и первые новые лекарственные средства за 50 л...т, однако сохраняется губительное отставание во внедрении этих нововведений в практику и обеспечения доступа к ним для уязвимых и социально ущемленных групп населения, в том числе заключенных, людей, живущих с ВИЧ, внутренних и внешних мигранты и наркопотребителей
more
3rd Edition – July 2017
www.msfaccess.org
Supplement Article
J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 www.jaids.com
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Report: A survey conducted among the 27 high MDR-TB burden countries.
March – July 2015
Stop TB Partnership in collaboration with Medecins Sans Frontieres (MSF).
Accessed November 2017.
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more